Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: Oregano and Basil Leaves and Coronary Artery Disease Primary completion pushed from Sep 28, 2026 to Dec 21, 2026 Shahid Beheshti University of Medical SciencesNot applicable NCT07123181
  2. Minor: Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia) Primary and study completion pushed from Oct 2026 to Apr 2027 University of Wisconsin, MadisonNot specified NCT04785989
  3. Minor: Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study Primary completion pushed from Dec 31, 2026 to May 31, 2027 Do Hyun ParkNot specified NCT07030348
  4. Minor: Eye-Tracking Alcohol Warning Primary completion pushed from Oct 1, 2027 to Nov 1, 2027 University of MiamiNot applicable NCT07852013
  5. Minor: Photoplethysmography-Based Machine Learning Algorithm for Early Atrial Fibrillation Detection: A Prospective Validation Study Primary completion pushed from Aug 2026 to Nov 2026 Seerlinq s. r. o.Not specified NCT07749183
  6. Minor: Low or High Dietary Fiber Diet on Volatile Organic Compounds in Exhaled Breath of Healthy Individuals Primary completion pushed from Nov 2026 to Feb 2027 Örebro University, SwedenNot applicable NCT07594600
  7. Minor: Hybrid Breastfeeding Education in Late Pregnancy: Effects on Antenatal Attachment and Breastfeeding Primary completion pushed from Jun 14, 2026 to Sep 12, 2026 Emel GÜÇLÜ CİHANNot applicable NCT07478341
  8. Minor: Can Ultrasound-Guided Fascial Plane Blocks Reduce Postoperative Pulmonary Complications After Major Abdominal Surgery? Primary completion pushed from Aug 1, 2026 to Dec 1, 2026 Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalNot specified NCT07394816
  9. Minor: Beamion LUNG-3 · Adjuvant Zongertinib vs Standard Treatment · Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations Trial sites expanded: 202 → 205 locations Boehringer IngelheimPhase 3 NCT07195695
  10. Minor: EloraTZP · Obesity or Overweight and Type 2 Diabetes Trial sites expanded: 75 → 96 locations Eli Lilly and CompanyPhase 3 NCT07881458
  11. Minor: QTX-2101 · Acute Promyelocytic Leukemia Trial sites expanded: 36 → 39 locations Quetzal TherapeuticsPhase 3 NCT07504458
  12. Minor: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) Trial sites expanded: 314 → 317 locations Merck Sharp & Dohme LLCPhase 3 NCT06393374
  13. Minor: Ivonescimab for First-line Treatment of Metastatic NSCLC · High PD-L1 Trial sites expanded: 285 → 292 locations Summit TherapeuticsPhase 3 NCT06767514
  14. Minor: Stroke and Systemic Embolism Prevention · Atrial Fibrillation Trial sites expanded: 66 → 84 locations Regeneron PharmaceuticalsPhase 3 NCT07626411
  15. Minor: How a New Pneumococcal Vaccine Works in Infants Trial sites expanded: 130 → 134 locations PfizerPhase 3 NCT07629440
  16. Minor: Ravulizumab · Primary IgAN Trial sites expanded: 15 → 19 locations Alexion Pharmaceuticals, Inc.Phase 3 NCT07024563
  17. Minor: ELEVATE-LIVER · Survodutide Helps Improve Heart Structure and Function · Overweight or Obesity and Fatty Liver Disease Trial sites expanded: 45 → 55 locations Boehringer IngelheimPhase 3 NCT07850063
  18. Minor: Pegozafermin · Compensated Cirrhosis Due to MASH Trial sites expanded: 330 → 335 locations Hoffmann-La RochePhase 3 NCT06419374
  19. Minor: Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens · Relapsed/Refractory Multiple Myeloma (RRMM) Trial sites expanded: 53 → 60 locations Regeneron PharmaceuticalsPhase 3 NCT07222761
  20. Minor: Intravitreal Injection of 4D-150 · Diabetic Macular Edema (DME) Trial sites expanded: 92 → 95 locations 4D Molecular TherapeuticsPhase 3 NCT07867080
  21. Minor: KarXT · Manic Episodes in Bipolar-I Disorder (BALSAM-3) Trial sites expanded: 182 → 191 locations Bristol-Myers SquibbPhase 3 NCT06929273
  22. Minor: Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone · Newly Diagnosed Previously Untreated Primary Immune Thrombocytopenia (ITP) Trial sites expanded: 3 → 21 locations AmgenPhase 3 NCT07700238
  23. Minor: CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis Trial sites expanded: 35 → 40 locations Medipost, Inc.Phase 3 NCT07339111
  24. Minor: Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy Trial sites expanded: 28 → 46 locations argenxPhase 2 NCT07287982
  25. Minor: Mivelsiran · Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD) Trial sites expanded: 10 → 20 locations Alnylam PharmaceuticalsPhase 2 NCT07636811